ClinicalTrials.gg
RecruitingNCT07056582Updated Jul 9, 2025

Pre-emptive Analgesia Using Nebulized Ketamine Versus Nebulized Dexmedetomidine in Endoscopic Nasal Surgeries

An interventional study of Dexmedetomidine and Ketamine in Nose Diseases, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Sohag University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

this study aims to compare the efficacy of pre-emptive nebulized ketamine versus nebulized dexmedetomidine for post operative pain relief in endoscopic nasal surgery

02

Conditions studied

  • Nose Diseases

Browse trials for

03

In context

Nose Diseases

22 studies on the registry are indexed under Nose Diseases; 9 are open to participants now.

This study's planned enrollment of 105 is close to the median of 99 across 18 interventional studies indexed under Nose Diseases.

Browse Nose Diseases studies →

Lead sponsor

Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients between the ages of 20 and 60,
  • both sexes,
  • physical status I to II
  • ≥18≤30 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • patients with advanced respiratory, renal, hepatic, neurological, or psychiatric disease, pregnant or nursing women.
  • patients with a history of allergies to any study drugs.
  • patients who had used central nervous system depressants or analgesics within the previous 24 hours.
  • patients with hypertension, hypotension, or bradycardia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    group D : will receive dexmedetomidine

    Patients will receive nebulized dexmedetomidine 50 μg (0.5 ml +normal saline 0.9% up to 3 ml) 15 minutes prior to the onset of surgery.

    Drug: Dexmedetomidine

  • Active comparator
    group K : will receive ketamine

    patients will receive nebulized ketamine 50 mg (1 ml + normal saline 0.9%up to 3 ml) 15 minutes prior to the onset of surgery.

    Drug: Ketamine

  • Placebo comparator
    group C: will receive .9% saline

    Patients will receive nebulized normal saline 0.9% (3 ml) 15 minutes prior to the onset of surgery.

    Drug: 0.9%sodium chloride

Interventions

  • patients in this group will receive nebulized Dexmedetomidine before onset of surgery

  • patients in this group will receive nebulized ketamine before onset of surgery

  • Drug0.9%sodium chloride

    patients in this group will receive nebulized 0.9% normal saline before onset of surgery

06

What researchers measure

Primary outcomes

  1. This study aims to assess the efficacy of nebulized dexmedetomidine vs nebulized ketamine to achieve good postoperative pain management in patients undergoing endoscopic nasal surgeries.

    post operative pain management by VAS

    Time frame: 24 hours after operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Parthasarathy S, Krishnapriyanka KJ, Saravanan B. Effectiveness of pre-emptive nerve block on opioid consumption in patients undergoing nasal surgery under general anaesthesia: A double-blinded randomised controlled study. Indian J Anaesth. 2022 Feb;66(2):133-139. doi: 10.4103/ija.ija_813_21. Epub 2022 Feb 24. PubMed 35359478 ↗
  • Prasant NVSN, Mohapatro S, Jena J, Moda N. Comparison of Preoperative Nebulization with 4% Lignocaine and Ketamine in Reduction of Incidence of Postoperative Sore Throat. Anesth Essays Res. 2021 Jul-Sep;15(3):316-320. doi: 10.4103/aer.aer_105_21. Epub 2022 Feb 14. PubMed 35320968 ↗
  • Cai Y, Xu H, Yan J, Zhang L, Lu Y. Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury. Mol Med Rep. 2014 May;9(5):1542-50. doi: 10.3892/mmr.2014.2034. Epub 2014 Mar 10. PubMed 24627001 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 9, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Oct 20, 2025
CompletionEst.
Oct 20, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07056582
Lead sponsor
Sohag University
Responsible party
Ahmed Thabet Abdelhameed (Resident , Anesthesia , Surgical Icu , Pain management Faculty of Medicine Sohag university, Sohag University) — Principal investigator
First posted
Jul 9, 2025
Start date
Apr 14, 2025
Primary completion
Oct 20, 2025 (estimated)
Completion
Oct 20, 2025 (estimated)
Last update
Jul 9, 2025

Study contacts

Ahmed T Abdelhameed, Resident
Contact
ahmedthanocloser460@gmail.com
01012833899
Hala M Hashem, Professor
Contact
01004385249

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Ketamine

Start the discussion